Chronic Somatic Syndromes Consortium
May 31, 2007
7:30 – 8:00
8:00 – 8:30
Welcome and introductions
8:30 – 10:00
Is there a consensus regarding the epidemiology, underlying mechanisms, and most effective treatments of these conditions?
D.J. Clauw UM
Before considering potential projects and deliverables of the consortium, we will first determine whether we can reach a consensus regarding these issues. Dr. Clauw will present a “straw-man” model for the group to comment upon.
10:00 – 10:15
10:15 – 12:30
How are these illnesses now viewed by different constituencies?
Even if thought leaders in these fields all agree on the above issues, these views might not be held by a variety of different constituencies that would need to be convinced of this new view. The speakers in this section will present the challenges and opportunities in these areas from each perspective.
|10:15 – 10:45
How do sub-specialists view these illnesses?
|E.A. Mayer UCLA|
|10:45 – 11:15
How do primary care physicians view these illnesses?
|K. Kroenke IU|
|11:15 – 11:45
The CDC/NIH/government perspective
|W.C. Reeves CDC,
Multiple NIH Researchers
|11:45 – 12:30
The Industry Perspective. A representative from each of the pharma companies co-sponsoring the event will be asked to speak briefly regarding how they view this spectrum of illness, what types of consortium projects they may be willing to support, and what types of constraints they have regarding funding of such endeavors.
12:30 – 1:30
1:30 – 3:00
Consortium members and industry guests can self-select the working group meeting(s) they would like to attend. Each of these working groups will address the same set of questions:
- What could be done in this area?
- Who should be involved?
- What would it cost?
- Who would fund this effort?
- Action plan for moving forward
|Physician education programs / treatment guidelines||T.L. Schwenk UM|
|Re-defining these illnesses (fibromyalgia clinical definition, primary care definition for chronic somatic syndrome)||D.J. Clauw
|Validating and using biomarkers for drug development||E.A. Mayer UCLA|
|Using systems biology to better diagnose and treat this spectrum of illness||W. Maixner UNC|
|Improved outcome measures||D.A. Williams UM|
3:00 – 5:00
Reports from each working group regarding recommendations for moving forward, followed by a plan for the future of the consortium.